A narrative synthesis of research with 5-MeO-DMT
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background: 5-Methoxy- N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring, short-acting psychedelic tryptamine, produced by a variety of plant and animal species. Plants containing 5-MeO-DMT have been used throughout history for ritual and spiritual purposes. The aim of this article is to review the available literature about 5-MeO-DMT and inform subsequent clinical development. Methods: We searched PubMed database for articles about 5-MeO-DMT. Search results were cross-checked against earlier reviews and reference lists were hand searched. Findings were synthesised using a narrative synthesis approach. This review covers the pharmacology, chemistry and metabolism of 5-MeO-DMT, as well epidemiological studies, and reported adverse and beneficial effects. Results: 5-MeO-DMT is serotonergic agonist, with highest affinity for 5-HT 1A receptors. It was studied in a variety of animal models, but clinical studies with humans are lacking. Epidemiological studies indicate that, like other psychedelics, 5-MeO-DMT induces profound alterations in consciousness (including mystical experiences), with potential beneficial long-term effects on mental health and well-being. Conclusion: 5-MeO-DMT is a potentially useful addition to the psychedelic pharmacopoeia because of its short duration of action, relative lack of visual effects and putatively higher rates of ego-dissolution and mystical experiences. We conclude that further clinical exploration is warranted, using similar precautions as with other classic psychedelics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Henry, J. D., & Crawford, J. R. (2005) · British Journal of Clinical Psychology · doi:10.1348/014466505x29657 · Cited by 5,801 · cited 3×
“In both studies, compared to baseline, the ratings of mindfulness facets increased (measured with Five Facets Mindfulness questionnaire, FFMQ-15; Gu et al., 2016), while ratings of depression and anxiety decreased (measured with Depression, Anxiety and Stress scale, DASS-21 (Henry and Crawford, 2005) or with Brief Sym…”
MethodGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…trials assessing psilocybin-assisted psychotherapy have been reported in unipolar mood disorders and anxiety (Carhart-Harris et al., 2016, 2018; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and substance use disorders (Bogenschutz et al., 2015, 2018; Johnson et al., 2014;…”
BackgroundSelf-citationRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“…and encouraging early phase clinical trials assessing psilocybin-assisted psychotherapy have been reported in unipolar mood disorders and anxiety (Carhart-Harris et al., 2016, 2018; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and substance use disorders (Bogenschutz et al.,…”
BackgroundSelf-citationPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“Over the past two decades, research has resumed and encouraging early phase clinical trials assessing psilocybin-assisted psychotherapy have been reported in unipolar mood disorders and anxiety (Carhart-Harris et al., 2016, 2018; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and substance use disorders…”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 1×
“…and encouraging early phase clinical trials assessing psilocybin-assisted psychotherapy have been reported in unipolar mood disorders and anxiety (Carhart-Harris et al., 2016, 2018; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016) and substance use disorders (Bogenschutz et al.,…”
BackgroundSelf-citationGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 2×
“For example, hallucinogenic and non-hallucinogenic 5-HT2A agonists differentially activate second messenger pathways (González-Maeso et al., 2007).”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 2×
“, 2016) and substance use disorders (Bogenschutz et al., 2015, 2018; Johnson et al., 2014; Noorani et al., 2018).”
BackgroundSelf-citation
Cited by
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06221-6 · Cited by 100
“1 3 Psychedelics used in clinical trials, ranging from the short acting 5-methoxy-N,N-dimethyltryptamine (5-MEO-DMT), to longer acting psilocybin, are united in eliciting recognisable subjective effects (‘trips’) at common doses (Ermakova et al. 2021; Nichols 2016).”
Self-citationReckweg, J. T., van Leeuwen, C. J., Henquet, C., van Amelsvoort, T., Theunissen, E. L., Mason, N. L., Paci, R., Terwey, T. H., & Ramaekers, J. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1133414 · Cited by 96
“5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a serotonergic psychedelic from the tryptamine class, that primarily acts as an agonist at the 5-HT1A and 5-HT2A receptors (1, 2), and that, when delivered via pulmonary inhalation, has a rapid onset (about 5–10 s) and a short duration (about 5–30 min) of psychoactive ef…”
BackgroundSpringtime for psychopharmacology
Bird, C., & Young, A. H. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221085764
Metadata
- Authors
- Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-10-19
- Volume
- 36
- Issue
- 3
- Pages
- 273-294
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3205688202
- Cited by
- 86
- References
- 40
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A narrative synthesis of research with 5-MeO-DMT. https://app.cochat.ai/papers/10.1177/02698811211050543
- The paper
- Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2022). A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211050543
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.